Compositions for treating CMT and related disorders

1. A pharmaceutical composition comprising, as active ingredients:

(i) baclofen or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 300 μg/kg of a human subject,

(ii) sorbitol or a pharmaceutically acceptable salt thereof, and

(iii) naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 100 μg/kg of the human subject;

and a pharmaceutically suitable excipient or carrier.

2. The composition according to claim 1 , wherein said composition comprises baclofen or a pharmaceutically acceptable salt thereof in an amount between about 10 and about 200 μg/kg of the human subject.

3. The composition according to claim 1 , wherein said composition comprises naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 50 μg/kg of the human subject.

4. The composition according to claim 1 , wherein said composition comprises baclofen or a pharmaceutically acceptable salt thereof in an amount from between about 10 and about 200 μg/kg of the human subject and naltrexone or a pharmaceutically acceptable salt thereof in an amount from between about 1 and about 50 μg/kg of the human subject.

5. The composition according to claim 1 , wherein the baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are present in an amount effective to treat Charcot-Marie Tooth Disease Type 1A (CMT1A) in the human subject when administered once, twice, or three times daily to the human subject.

6. The composition according to claim 1 , wherein the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol.

7. The composition according to claim 1 , wherein the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen.

8. The composition according to claim 1 , wherein the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen and the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol.

9. The composition according to claim 1 , wherein the composition contains no additional active agents.

10. The composition according to claim 1 , wherein the composition is formulated for oral administration.

11. The composition according to claim 1 , wherein the composition is a liquid formulation.

12. The composition according to claim 1 , wherein the composition is a liquid formulated for oral administration.

13. A unit dosage form comprising:

(i) baclofen or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 300 μg/kg of a human subject,

(ii) sorbitol or a pharmaceutically acceptable salt thereof, and

(iii) naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 100 μg/kg of the human subject; and

a pharmaceutically acceptable excipient or carrier.

14. The unit dosage form according to claim 13 , comprising baclofen or a pharmaceutically acceptable salt thereof in an amount between 10 and 200 μg/kg of the human subject and naltrexone or a pharmaceutically acceptable salt thereof in an amount between 1 and 50 μg/kg of the human subject.

15. The unit dosage form according to claim 13 , wherein the baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are present in an amount effective to treat Charcot-Marie-Tooth Disease Type 1A (CMT 1 A) in the human subject when administered once, twice, or three times daily to the human subject.

16. The unit dosage form according to claim 13 , wherein the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen and the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol.

17. The unit dosage form according to claim 13 , wherein the unit dosage form contains no additional active agents.

18. The unit dosage form according to claim 13 , wherein the unit dosage form is a liquid formulated for oral administration.

19. A patient pack comprising a liquid formulation for oral administration, comprising a composition comprising:

(i) baclofen or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 300 μg/kg of a human subject,

(ii) sorbitol or a pharmaceutically acceptable salt thereof, and

(iii) naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 100 μg/kg of the human subject;

a pharmaceutically acceptable excipient or carrier; and, optionally, instructions for administration of the liquid formulation.

20. The patient pack according to claim 19 , comprising baclofen or a pharmaceutically acceptable salt thereof in an amount between about 10 and about 200 μg/kg of the human subject and naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 50 μg/kg of the human subject.

21. The patient pack according to claim 19 , wherein the baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof are present in an amount effective to treat Charcot-Marie Tooth Disease Type 1A (CMT1A) in the human subject when the composition is administered once, twice, or three times daily to the human subject.

22. The patient pack according to claim 19 , wherein the liquid formulation comprises divided doses.

23. The patient pack according to claim 19 , wherein each of the divided doses comprises baclofen or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 300 μg/kg of a human subject and naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 100 μg/kg of the human subject.

24. The patient pack according to claim 19 , wherein each of the divided doses comprises baclofen or a pharmaceutically acceptable salt thereof in an amount between about 10 and about 200 μg/kg of a human subject and naltrexone or a pharmaceutically acceptable salt thereof in an amount between about 1 and about 50 μg/kg of the human subject.

25. The patient pack according to claim 19 , wherein the baclofen or a pharmaceutically acceptable salt thereof is RS baclofen and the sorbitol or a pharmaceutically acceptable salt thereof is D-sorbitol.